ADARx Pharmaceuticals Expands Leadership Team, Appointing Christopher Prentiss as CFO
ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer
SAN DIEGO--(BUSINESS WIRE)--Sep 28, 2022--
ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the expansion of their leadership team through the appointment of Christopher Prentiss as Chief Financial Officer.
“I am delighted to welcome Chris to ADARx with his extensive financial experience in the pharmaceutical industry,” said Dr. Zhen Li, President, and Chief Executive officer of ADARx. “As ADARx continues to grow, our evolving leadership structure reflects the expanding development needs of our organization as we enter clinical trials. Chris’s experience in the development and launch of pharmaceutical products directly supports our goal of turning cutting-edge science into life-saving therapeutics.”
Mr. Prentiss joins ADARx as ADX-324 for the treatment of hereditary angioedema is set to start phase I clinical trials at the end of the year. ADARx has two additional drug candidates set to enter clinical trials next year and an extensive pipeline to follow.
